ReShape Lifesciences Inc. (RSLS)

NASDAQ: RSLS · IEX Real-Time Price · USD
0.183
+0.001 (0.72%)
Mar 28, 2024, 1:10 PM EDT - Market open

Company Description

ReShape Lifesciences Inc., a medical device company, provides products and services that manages and treat obesity and metabolic diseases in the United States, Australia, Europe, and internationally.

The company's product portfolio includes Lap-Band System, a minimally invasive long-term treatment of severe obesity and more invasive surgical stapling procedures, such as the gastric bypass or sleeve gastrectomy and ReShape Vest system, a laparoscopically implantable device to enable weight loss and stomach preservation.

It also offers ReShapeCare virtual health coaching program, a program that supports healthy lifestyle changes for all medically managed weight-loss patients; and ReShape Diabetes Bloc-Stim Neuromodulation, a technology that is in preclinical development for the treatment of type 2 diabetes mellitus.

In addition, the company provides Obalon Balloon System, a swallowable capsule used to track and display the location of the balloon during placement.

The company was formerly known as EnteroMedics Inc. and changed its name to ReShape Lifesciences Inc. in 2017.

ReShape Lifesciences Inc. was incorporated in 2002 and is headquartered in San Clemente, California.

ReShape Lifesciences Inc.
ReShape Lifesciences logo
Country United States
Founded 2002
IPO Date Nov 15, 2007
Industry Medical Devices
Sector Healthcare
Employees 40
CEO Paul F. Hickey

Contact Details

Address:
1001 Calle Amanecer
San Clemente, California 92673
United States
Phone (949) 429-6680
Website reshapelifesciences.com

Stock Details

Ticker Symbol RSLS
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001371217
CUSIP Number 761123603
ISIN Number US76090R2004
Employer ID 48-1293684
SIC Code 3845

Key Executives

Name Position
Dan W. Gladney Executive Chair
Paul F. Hickey Chief Executive Officer, President and Director
Thomas Stankovich Chief Financial Officer
Dr. Mark B. Knudson Ph.D. Co-Founder and Special Advisor to the Chief Executive Officer
Dr. Katherine S. Tweden Ph.D. Co-Founder
Al Diaz Vice President of Operations and Research & Development
Dr. Dov Gal D.V.M., M.B.A. Vice President of Regulatory Clinical Quality and Compliance Officer
Jody B. Dahlman Director of Communications
Naqeeb A. Ansari Senior Vice President of Global Commercial Operations

Latest SEC Filings

Date Type Title
Jun 25, 2021 EFFECT Notice of Effectiveness
Jun 25, 2021 EFFECT Notice of Effectiveness
Jun 25, 2021 EFFECT Notice of Effectiveness
Jun 25, 2021 EFFECT Notice of Effectiveness
Jun 25, 2021 EFFECT Notice of Effectiveness
Jun 25, 2021 EFFECT Notice of Effectiveness
Jun 25, 2021 EFFECT Notice of Effectiveness
Jun 25, 2021 EFFECT Notice of Effectiveness
Jun 25, 2021 EFFECT Notice of Effectiveness
Jun 25, 2021 EFFECT Notice of Effectiveness